Bookmark and Share
BioAssay: AID 2164

Probe Development Summary of Inhibitors of 12-hLO (12-human lipoxygenase)

Lipoxygenases are a class of non-heme iron-containing enzymes. There are three major human lipoxygenses: 5-, 12, and 15-hLO, whose primary enzymatic difference lies in their site-specific oxidation of arachidonic acid. The products of lipoxygenases are precursors of hormones such as leukotrienes and lipoxins, which have been implicated as critical in a variety of inflammatory diseases and more ..
_
   
AID: 2164
Data Source: NCGC (LPOX101)
BioAssay Type: Summary, Candidate Probes/Leads with Supporting Evidence
Depositor Category: NIH Molecular Libraries Probe Production Network
BioAssay Version:
Deposit Date: 2009-11-27
Modify Date: 2010-04-29
Target
Related Experiments
Show more
AIDNameTypeComment
1452qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase)Confirmatorydepositor-specified cross reference: qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase)
2162Confirmation qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase)Confirmatorydepositor-specified cross reference: Confirmation qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase)
2163Cuvette-Based Assay for Inhibitors of 12-hLO (12-human lipoxygenase): 8HQ Series - Round 1Confirmatorydepositor-specified cross reference: Cuvette-Based Assay for Inhibitors of 12-hLO (12-human lipoxygenase)
2584qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase) - Confirmatory and Counterscreen DataConfirmatorydepositor-specified cross reference: qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase) - Confirmatory and Counterscreen Data
493209Activators of 12-hLO (12-human lipoxygenase): 12hLO Cuvette-Based Hit Validation Assay of Followup CompoundsConfirmatorydepositor-specified cross reference
493216Inhibitors of 12-hLO (12-human lipoxygenase): Cuvette-Based Hit Assay for Validation of Followup CompoundsConfirmatorydepositor-specified cross reference
493219Inhibitors of 12-hLO (12-human lipoxygenase): 15hLO-1 Cuvette-Based Activation Counterscreen Assay for 12hLO Followup CompoundsConfirmatorydepositor-specified cross reference
493220Inhibitors of 12-hLO (12-human lipoxygenase): 15hLO-1 Cuvette-Based Inhibition Counterscreen Assay for 12hLO Followup CompoundsConfirmatorydepositor-specified cross reference
504581Inhibitors of 12-hLO: PBS Stability ProfilingOtherdepositor-specified cross reference
504590Inhibitors of 12-hLO: Aqueous Solubility ProfilingOtherdepositor-specified cross reference
504605Inhibitors of 12-hLO: Mouse Liver Microsome Stability ProfilingOtherdepositor-specified cross reference
504610Inhibitors of 12-hLO: Mouse Plasma Stability ProfilingOtherdepositor-specified cross reference
504611Inhibitors of 12-hLO: Caco-2 Permeability ProfilingOtherdepositor-specified cross reference
504612Inhibitors of 12-hLO: Efflux Ratio ProfilingOtherdepositor-specified cross reference
Description:
Source: NIH Chemical Genomics Center [NCGC]
Assay Submitter: Holman, T.R., University of California, Santa Cruz
Screening Center PI: Christopher P. Austin, NIH
Probe Development: NIH Chemical Genomics Center [NCGC]
NIH Grant Number: MH081283-01

Lipoxygenases are a class of non-heme iron-containing enzymes. There are three major human lipoxygenses: 5-, 12, and 15-hLO, whose primary enzymatic difference lies in their site-specific oxidation of arachidonic acid. The products of lipoxygenases are precursors of hormones such as leukotrienes and lipoxins, which have been implicated as critical in a variety of inflammatory diseases and cancers. 15-hLO-1 has higher expression in human prostate tumors, compared with adjacent tissue, and this expression correlates with the virulency of the cancer. Also, the 15-hLO-1 metabolite of linoleic acid, 13-(S)-hydroxyoctadecadienoic acid, is detected in adenocarcinoma tissue, indicating a pro-tumorigenic role in prostate tumor development for 15-hLO-1.

Inhibitors of lipoxygenase are found in three broad categories reflecting the mode of action: reductive, catalytic and allosteric. The reductive inhibitors convert the active, ferric enzyme to the inactive, ferrous form. The catalytic inhibitors act as competitive inhibitors. The allosteric inhibitors, are however different in their kinetic properties and do not bind to the catalytic site, but an allosteric site, whose exact position is not known. The presence of such a site allows for targeting two sites in lipoxygenase, the allosteric and the catalytic sites, which may have different SARs and different pharmacophore profiles.

The overall goal of Molecular Libraries Initiative Grant MH081283-01 is to screen against three lipoxygenase isozymes; reticulocyte 15-hLO-1, epidermal 15-hLO-2 and platelet 12-hLO, with the aim of finding selective inhibitors specific for each isozyme. The design of selective inhibitors of lipoxygenases has been particularly challenging in the field.

This particular summary assay focuses on small molecule probe development of 12-hLO. A chemical probe for this project is defined as follows: a small molecule compound which inhibits 12-hLO enzyme with an IC50 of 1 uM or less in the secondary cuvette assay. A desired but not required characteristic is selectivity. A probe should preferably inhibit the 12hLO enzyme at an IC50 10 times lower than it would 15-hLO-1 and 15-hLO-2.


Recommendations for the scientific use of probe described in this assay:

Small molecule probes from this project will exhibit potent inhibition of 12-hLO, yet will not inhibit the closely related 15-hLO-1 and 15-hLO-2. The probe should be useful for in vitro studies of 12-hLO but may also be utilized as a starting point for the development of 12-hLO effectors in cellular or animal models.
Protocol
Please see related BioAssay(s) for all protocols relevant to this probe development project: AID 1452
Comment
Related BioAssays:

AID 1452: This assay is main primary screen for inhibitors of 12-hLO (12-human lipoxygenase). A collection of 151,834 compounds were screened in a concentration response dependent manner.

This summary assay will be updated as additional screens are run and small molecule probes have been developed.
Categorized Comment - additional comments and annotations
From MLP Probe Report:
Probe count: 2
MLP Probe ML# for probe 1: ML127
PubChem Substance ID (SID) for probe 1: 85736374
PubChem Compound ID (CID) for probe 1: 44460175
Probe type for probe 1: Inhibitor
IC50/EC50 (nM) for probe 1: 1000
Target for probe 1: 12hLO (gi: 154426292)
Disease relevance for probe 1: Cancer
Anti-target for probe 1: 15hLO-1
Fold selectivity for probe 1: 100
NCBI Book chapter link for probe 1: http://www.ncbi.nlm.nih.gov/books/NBK56235/ (ID: 2509892)
Grant number for probe 1: MH081283-01A1
MLP Probe ML# for probe 2: ML355
PubChem Substance ID (SID) for probe 2: 160844040
PubChem Compound ID (CID) for probe 2: 70701426
Probe type for probe 2: Inhibitor
IC50/EC50 (nM) for probe 2: 290
Target for probe 2: 12-Lox (gi: 154426292)
Disease relevance for probe 2: Cancer, Diabetes
Anti-target for probe 2: 15-Lox
Grant number for probe 2: MH081283
PubMed Publication ID (PMID) for probe 2: 24684213
NCBI Book chapter title for probe 1: Selective Small Molecule Inhibitors of 12-Human Lipoxygenase (12-hLO)
Additional Information
Grant Number: MH081283-01

PageFrom: